Environmental

ZBH’s R&D intensity near 5.4% of revenue supports product redesign and lower-material solutions, but peers in medtech often invest similarly, limiting relative advantage.

The company’s capital structure shows moderate leverage, which can constrain funding flexibility for sustainability upgrades versus lower-debt peers, though it is not an acute environmental differentiator.

No direct emissions, energy, or waste disclosures were provided, so the environmental score is anchored mainly on operational discipline rather than demonstrated peer-leading decarbonization.

In a regulated medtech peer set, ZBH appears broadly average on environmental execution because available metrics show discipline, but not clear structural leadership.

Social

ZBH’s high gross margin and ongoing R&D spend indicate capacity to support product quality, training, and patient-safety processes, which is favorable versus less-resourced peers.

The low stock-based compensation burden suggests less dilution-driven pressure on workforce incentives, supporting a more stable employee value proposition than many growth-oriented peers.

As a medical-device manufacturer, product safety and clinical performance are material social risks, and ZBH’s disclosed metrics imply disciplined investment, though peer-specific incident data is unavailable.

Relative to peers, ZBH looks stronger on social resilience because it combines innovation spending with manageable capital demands, reducing execution strain on quality systems.

Governance

ZBH’s debt-to-equity ratio of 0.59 suggests moderate balance-sheet discipline, but peers with lower leverage typically have stronger governance flexibility and risk control.

R&D at 5.4% of revenue indicates management commitment to long-term product development, yet the absence of board, audit, and compliance disclosures limits a stronger governance assessment.

Stock-based compensation at 1.1% of revenue is restrained versus many peers, which can indicate more conservative incentive design and lower shareholder-alignment risk.

Overall governance appears average to slightly above average versus medtech peers because available capital-allocation metrics are disciplined, but key oversight disclosures are missing.

Overall Score

ZBH’s ESG positioning is broadly average to slightly above average versus medtech peers, supported by disciplined capital allocation and steady innovation, but limited disclosure prevents a stronger rating.

Score Driver: Disciplined Capital Allocation With Moderate Leverage And Restrained Compensation Intensity